APAntonia Pearson

Antonia Pearson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antonia Pearson has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Feasibility evaluation of a virtual lifestyle intervention for early-stage breast cancer survivors undergoing chemotherapy

    by Sim Yee (Cindy) Tan, Isaac Yeboah Addo, Gemma Collett, Emily Price, Eliza R Macdonald, Shannon Gerber, Jane Turner, Liane Lee, Hau Yi Yau, Jaclyn Spencer, et al.

    Background: Weight gain and physical inactivity during chemotherapy for patients with early-stage breast cancer are common. We sought to investigate the feasibility of a virtual lifestyle (exercise and diet) intervention for breast cancer survivors during chemotherapy. Methods: This single-arm phase 2 trial delivered 12 weekly 1-hour telehealth sessions of supervised exercise and diet education to breast cancer survivors (patients with stage I-III disease) starting neoadjuvant chemotherapy. Screening, recruitment, intervention, and study assessments completed at baseline (T0), immediately after the intervention (T1), and 3 months after the intervention (T2) were conducted by telehealth in 2022-2023. The primary outcome was that at least 60% of participants achieved 50% of the predetermined exercise and dietary goals. Secondary outcomes were acceptability (participation, attendance, completion), physical health, and lifestyle outcomes. Results: Of 73 referrals, 60 individuals were eligible, 58 (97%) provided consent, 51 (85%) commenced the intervention, and 34 (57%) completed at least 1 postintervention assessment (completion rate = 67%). The mean (SD) age of participants was 51 (8.8) years, and 50% of participants were receiving neoadjuvant chemotherapy. Attendance was lower for exercise than for diet sessions (44% vs 62% attended ≥75% sessions). At T1, 36% of participants adhered to at at least 50% of the preset goals, improving at T2 (62.5%). Weight was not statistically significantly different between T0 and T1 (P = .199) but increased substantially at T2 (P = .018). Average waist circumference was reduced at T1 (‒1.9 cm, P = .014) and at T2 (‒3.3 cm, P < .001). Weekly exercise time increased by 38.5 minutes from T0 to T1 (P = .038), and the proportion of participants who met exercise guidelines improved from 6% (T0) to 41% (T2). Conclusion: Our primary outcome was not achieved immediately after the intervention but was observed 3 months later. Individuals completing the intervention attended at least half the diet and exercise sessions during chemotherapy. Results of this study will inform design of a phase 3 study.


  • Open Access

    Genitourinary symptoms in women with breast cancer: frequency, severity and impact

    by Antonia Pearson, Haryana M. Dhillon, Jill Chen, Rachel Campbell, Janine Lombard, Martha Hickey, Belinda E. Kiely

    Purpose: To improve understanding of genitourinary symptoms (GUS) in women with breast cancer (BC). Methods: Women with BC completed a survey assessing the type, severity, and impact of GUS experienced, and perceptions of treatment options. Results: Surveys were completed by 506 women: median age 60 years (range 30 – 83). The majority reported: being sexually active (52%); currently taking endocrine therapy (58%); and having early-stage BC (84%). 69% had GUS, with some changing (5%) or stopping (4%) endocrine therapy as a result. Vaginal dryness was the most common symptom (62%), followed by pain during penetration (41%) and itch (33%). Only 44% recalled being warned by their cancer doctor that BC treatment can cause GUS, and 38% reported never being asked about GUS. Being uncomfortable talking to a male healthcare professional was a moderate or major barrier to accessing advice and treatment for GUS in 28% of respondents. A minority reported using vaginal: lubricants (40%); moisturisers (25%); or oestrogens (16%). Amongst those using vaginal oestrogens, 45% found they helped “quite a bit” or “very much”. The most frequently reported moderate to major barrier to using vaginal oestrogens was product information warning against use in women with BC. Conclusions: Although GUS are very common in women with BC, the majority of women in our study do not recall being warned or asked about these symptoms. Healthcare professionals should initiate conversations about GUS and treatment options with women with BC to help reduce the impact of these symptoms.


  • Open Access

    Measuring serum oestrogen levels in breast cancer survivors using vaginal oestrogens: a systematic review

    by Antonia Pearson, Jill Chen, Haryana M. Dhillon, Belinda E. Kiely

    Purpose: Vaginal oestrogens can be used to treat genitourinary symptoms in women with early breast cancer. Studies evaluating vaginal oestrogens have commonly measured serum oestrogen levels as a surrogate marker of safety, but methods vary. We sought to summarise the data on serum oestrogen measurement in women with breast cancer using vaginal oestrogens to better understand the methods, levels and reliability. Methods: We searched Medline, Embase, CENTRAL, SCOPUS and CINAHL from inception to October 2023 for clinical studies where serum oestrogen was measured in women with a history of early breast cancer using vaginal oestrogens. Studies with a reported testing methodology were included. Results: Nine studies met the inclusion criteria for this systematic review. Methods used to measure oestradiol and oestriol in selected studies included mass spectrometry and immunoassays; several studies used more than one with variable concordance. Mass spectrometry detected oestradiol levels down to a lower limit between 1.0 pg/mL and 3.0 pg/mL. Immunoassays such as ELISA (enzyme-linked immunosorbent assay), ECLIA (enhanced chemiluminiscence immunoassay) and RIA (radioimmunoassay) had lower detection limits ranging between 0.8 pg/mL and 10 pg/mL. Studies were heterogeneous in testing techniques used, timing of testing, and the population including with subsequent varying results in the effect on oestrogens reported. Conclusions: Adopting consistent and standardised methods of measuring oestrogens in clinical trials involving women with early breast cancer on vaginal oestrogens is critical. Serum oestrogens are used as a surrogate marker of safety in this population, and good-quality data are necessary to enable clinicians and patients to feel confident in prescribing and taking vaginal oestrogens. Mass spectrometry, although more expensive, gives more reliable results when dealing with very low levels of oestrogens often found in women on aromatase inhibitors, compared to immunoassays.


  • Open Access

    What Is Women With Breast Cancers’ Experience And Perception Of Genitourinary Symptoms?

    by Antonia Pearson, Haryana M. Dhillon, Jill Chen, Janine Lombard, Martha Hickey, Belinda E. Kiely

  • Genitourinary symptoms in women with breast cancer: what do oncology health professionals think and do about them?

    by Antonia Pearson, Haryana M. Dhillon, Belinda E. Kiely

    Objectives We aimed to improve understanding of health professional knowledge and management of genitourinary symptoms (GUS) in women with early breast cancer (EBC). Methods A survey was sent to 872 health professionals caring for women with EBC. Questions addressed most common GUS seen, experience treating GUS, and attitudes to treatment options. Results 144 surveys were completed. Respondent characteristics: median age 50 years; 76% female; 42% medical oncologists; 24% nurses; 20% breast surgeons; 8% radiation oncologists. Most (68%) reported prescribing endocrine therapies for EBC, 99% were aware endocrine therapies can cause GUS, and 55% reported “often” or “always” asking patients on endocrine therapy if they have GUS. Respondents thought vaginal dryness was the most bothersome symptom for their patients (66%), followed by dyspareunia (11%). 81% of respondents reported seeing women stop endocrine therapy prematurely due to GUS. Respondents reported receiving “none” (19%) or “a little” (46%) training or education in managing GUS and only 16% reported feeling “very confident” managing GUS. The proportions of respondents reporting “often” and “very often” recommending the following vaginal treatments were: lubricants (81%); moisturisers (68%); oestrogens (21%); and laser (3%). Vaginal oestrogens were considered “safe” or “probably safe” by 77% and 90% of respondents for women with hormone receptor positive and negative EBC, respectively. Conclusions Despite health professionals frequently encountering GUS in women with EBC and seeing patients stop endocrine therapies prematurely, only 16% felt confident managing these symptoms. Education and training for health professionals are needed to better address this common problem.


  • Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases

    by Talia L. Fuchs, Antonia Pearson, Justine Pickett, Connie Diakos, Robert Dewar, David Chan, Alexander Guminski, Alexander Menzies, Sally Baron-Hay, Amy Sheen, et al.


  • Vaginal CO2 laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study

    by Antonia Pearson, Andrew Booker, Martin Tio, Gavin Marx

    Purpose Vulvovaginal atrophy (VVA) is a commonly reported issue among breast cancer patients, and its aetiology is multifactorial. Treatment is difficult in these women, particularly because the use of oestrogens has traditionally been discouraged. Vaginal laser treatment has been reported to improve symptoms. We aimed to assess the impact on symptoms and sexual function of vaginal laser in women with early breast cancer (EBC). Methods We performed a single-arm investigator initiated pilot study of female EBC patients with symptomatic VVA. A total of 3 vaginal laser treatments were administered 4 weeks apart. Questionnaires were completed at baseline, 4, 8 and 12 weeks. Our primary endpoint was symptomatic improvement of VVA at 12 weeks on 10 cm visual analogue scales. Our secondary endpoints were improvement in sexual function using the Female Sexual Function Index (FSFI) and patient-reported improvements in symptoms, sexual function and quality of life. Statistical analysis was performed with a Wilcoxon Signed Rank test. Results 26 patients were enrolled between February 2016 and August 2017. All patients were post-menopausal, 25 of whom had received anti-oestrogen therapy for their breast cancer. Questionnaire compliance was high (98%) and all patients received the three pre-planned treatments. There was significant improvement in each of the VVA symptoms: dryness (p < 0.001), itch (p < 0.001), burning (p = 0.003), dysuria (p < 0.001) and dyspareunia (p < 0.001). Patients also reported improvement in sexual function on the FSFI (p ≤ 0.001). Conclusions Patients receiving vaginal laser had improvement in VVA symptoms and sexual function. Further randomised sham-controlled trials are needed to further assess this treatment.


  • Vascular Resection and Reconstruction for Localized Pancreatic Cancer

    by Charles R. Scoggins, Ingrid M. Meszoely, Steven D. Leach, A. Scott Pearson